Short answer
PROCEPT BioRobotics Corp (PRCT) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces PROCEPT BioRobotics’ financial results for the quarter ended September 30, 2026.
PROCEPT BioRobotics Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces PROCEPT BioRobotics’ financial results for the quarter ended September 30, 2026
- Full quarterly results available in Exhibit 99.1, including operating performance and financial metrics
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $98.3M, up 18%, led by U.S. consumables up 21% and international revenue up 32%
- U.S. procedures 13,400, up 22%, with 62 HYDROS systems delivered and 106% handpieces per procedure
- Gross margin 66% versus 65%, but net loss widened to $26.5M and adjusted EBITDA loss to $9.8M
- Cash, equivalents and restricted cash $221.4M, down from $286.5M at December 31, 2025
- 2026 guidance reaffirmed: revenue $390M-$410M, procedures 54,000-56,000, adjusted EBITDA loss $30M-$35M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PROCEPT BioRobotics Corp 8-K filings
Get the next PRCT 8-K as it lands
Follow PRCT for push alerts, or ask the research agent what this filing means.